Posts tagged as

COMPPARE

COMPPARE Enrolls 1,000th Photon Patient

The COMPPARE Coordinating Center announced today that the study has enrolled its 1,000th photon prostate cancer patient to reach 67% of its photon cohort goal. COMPPARE Partner Site University of Maryland enrolled the 1,000th patient, followed closely by UNC REX Healthcare, Raleigh, NC,…

COMPPARE Newsletter: Spring/Summer 2022

A Message from Dr. Nancy Mendenhall As we near the completion of COMPPARE’s overall enrollment objective – a total of 3,000 patients – we are beginning to reflect and evaluate what we’ve learned thus far in creating and carrying out a large, multi-institutional pragmatic…

COMPPARE Enrolls 1,500th Proton Patient, Reaches Cohort Goal

The COMPPARE Coordinating Center announced today that the study has enrolled its 1,500th proton prostate cancer patient and has closed enrollment for the proton cohort. This goal was achieved in advance of the projected completion date of July 31, 2022. The proton cohort is divided into two groups: Pragmatic and…

COMPPARE Achieves 75% Enrollment Milestone

The COMPPARE Coordinating Center announced today that the study achieved 75% enrollment on May 3, 2022. COMPPARE realized both a remarkable overall accrual rate and a exceptional accrual rate of minorities, despite the ongoing challenges presented by COVID-19. In fact, the study stands to become a model for patient-centric clinical…

A Look at the New Technology Known as Theranostics

Brotherhood of the Balloon, a COMPPARE Partner Organization, reports on a new technology known as theranostics in the latest BOBtales newsletter. This approach combines molecular therapies (therapy) and paired molecular targeted imaging (diagnostics). In theranostics, a special diagnostic molecule is first…

COMPPARE Newsletter: Fall/Winter 2021-22

A Message from Dr. Nancy Mendenhall Our focus on IMRT enrollment has increased as we have become more aware of practice pattern changes that have impacted IMRT accrual, specifically the increased utilization of ultra-hypofractionated radiation (stereotactic body radiation therapy, or SBRT). Read Dr. Mendenhall’s message.

From Principles to Practice: Building Partnerships for Trust and Equity in Health Research with COMPPARE

On November 17, Dr. Nancy Mendenhall, COMPPARE Principal Investigator, and Charles Griggs, Minority Engagement Group Coordinator, participated in a special panel discussion entitled “From Principles to Practice: Building Partnerships for Trust and Equity in Health Research” during the 7th annual meeting of the Patient-Centered Outcomes Research Institute (PCORI). “This year’s…

COMPPARE Reaches Its Pragmatic Proton Patient Enrollment Goal

The COMPPARE Coordinating Center announced on September 1, 2021 that the study had reached its Pragmatic Proton enrollment goal of 900 patients, completing and closing that arm of the proton cohort. The 900th patient was enrolled by the Proton Therapy Treatment & Research Center of the Loma Linda University Medical…

Contact the COMPPARE Team